悪性リンパ腫　臨床と病理―ALTSGの研究から―

出版社： 先端医学社
著者：
発行日： 2005-02-25
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 4884071743
電子書籍版： 2005-02-25 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,170 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,585 円(税込)

購入する

商品紹介

本書は、悪性リンパ腫に対する新たな治療法の開発を目的に設立された成人リンパ腫治療研究会(ALTSG)による、活動の成果を集大成したもの。各病態とも臨床と病理の担当に分けたうえで、臨床では豊富な症例に基づいた解説を、病理では精度の高い診断に基づいて解説。また、すべての病理写真をカラーで掲載するとともに、ますます重要性が増している染色体分析についても網羅。リンパ腫治療の最前線を理解するために必携の書。

目次

  • 悪性リンパ腫　臨床と病理―ALTSGの研究から―

    ―目次―

    ■総論
    　１．ALTSGが志向するもの
    　　　―臨床研究の手法と病理central reviewの意義―
    　抄録-ALTSG Lymphoma Forum 2004
    　２．活動状況・各種統計
    　３．染色体異常-検査の方法と読み方-
    　　1．総論/染色体
    　　2．総論/染色体診断学
    　　3．総論/異常核型の記載例
    　　4．総論/腫瘍分子細胞遺伝学
    　　5．各論/B細胞腫瘍(B-cell neoplasms)
    　　6．各論/TおよびNK細胞腫瘍(T-cell and NK-cell neoplasms)
    　　7．各論/Hodgkinリンパ腫(Hodgkin lymphoma)
    　　8．各論/その他
    　　9．おわりに

    ■各論
    　Part.1　低悪性度B細胞リンパ腫
    　　１．低悪性度B細胞リンパ腫〜病理〜
    　　２．慢性リンパ球性白血病/前リンパ球性白血病/
    　　　　　ヘアリー細胞白血病
    　　３．濾胞性リンパ腫
    　　４．MALTリンパ腫
    　　５．マントル細胞リンパ腫
    　Part.2　中・高悪性度B細胞リンパ腫
    　　１．中・高悪性度B細胞リンパ腫〜病理〜
    　　２．びまん性大細胞型B細胞リンパ腫
    　　３．Burkittリンパ腫/白血病
    　　４．リンパ芽球白血病/リンパ腫
    　Part.3　T/NK細胞リンパ腫
    　　１．T/NK細胞リンパ腫〜病理〜
    　　２．末梢性T細胞リンパ腫
    　　３．節外性NK/T細胞リンパ腫
    　　４．成人T細胞白血病/リンパ腫
    　Part.4　Hodgkinリンパ腫
    　　１．Hodgkinリンパ腫〜病理〜
    　　２．Hodgkinリンパ腫

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

総論

P.7 掲載の参考文献
1) McKelvey EM, Gottlieb JA, Wilson HE et al:Hydroxydaunomycin (Adriamycin), combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493, 1976
PubMed
2) Yi PI, Coleman M, Saltz L et al:Chemotherapy for large cell lymphoma:a status update. Semin Oncol 17:60-73, 1990
PubMed
3) Goldie JH, Coldman AJ, Gudauskas GA et al:Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439-449, 1982
PubMed
4) Hirano M, Okamoto M, Maruyama F et al:Alternating non-cross-resistant chemotherapy for non-Hodgkin's lymphoma ofintermediate-grade and high-grade malignancy. A pilot study. Cancer 69:772-777, 1992
 
5) Fisher RI, Gaynor ER, Dahlberg S et al:Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
PubMed
6) The International Non-Hodgkin's Lymphoma Prognostic Factors Project:A prospective model for advanced non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
 
7) Wolf M, Matthews JP, Stone J et al:Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Ann Oncol 8 (suppl 1):S71-S75, 1997
 
8) Tilly H, Lepage E, Coiffier B et al:Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289, 2003
 
9) Pfreundschuh M, Trumper L, Kloess M et al:Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas:results of the NHL-Bl trial ofthe DSHNHL. Blood 104:634-641, 2004
 
P.28 掲載の参考文献
1) The Non-Hodgkin's Lymphoma Pathologic Classification Project:National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas:summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
PubMed
2) Harris NL, Jaffe ES, Stein H et al:A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
 
3) Jaffe ES, Harris NL, Stein H, Vardiman JW ed:In:World Health Organization Classification of Tumors. Pathology & Genetics. Tumor of Hematopoietic and Lymophoid Tissues. IARC Press, Lyon, 2001
 
4) Niitsu N, Okamoto M, Kuraishi Y et al:CyclOBEAP (cyclo-phosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma:a pilot study. The Adult Lymphoma Treatment Study Grotlp (ALTSG). Eur J Haematol 65:188-194, 2000
 
5) Lymphoma Study Group of Japanese Pathologists:The world health organization classification of malignant lymphomas in Japan:incidence of recently recognized entities. Pathol Int 50:696-702, 2000
 
6) The Non-Hodgkin's Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
 
P.58 掲載の参考文献
1)ISCN (1995):In:An International System for Human Cytogenetic Nomenclature.ed.by Mitelman F, S.Karger,Basel,1995
 
2)Eva Therman:In:Human Chromosome (2nd ed).Springer-Verlag,1986
 
3)Margaret JB,Turid K,Jack LS:In:The AGT Cytogenetics Laboratory Manual (3rd ed).Lippincott-Raven,Philadelphia,1997
 
4)外村晶:染色体異常-ヒトの細胞遺伝学-.朝倉書店,東京, 1978
 
5)牧野佐二郎:染色体-人類の細胞遺伝.医学書院,東京, 1979
 
6)阿部達生,藤田弘子:新染色体異常アトラス.南江堂,東京, 1997
 
7)阿部達生,鎌田七男,桜井雅温:腫瘍染色体アトラス.南江堂,東京,1986
 
8)Sandberg AA:In:The chromosomes in human cancer and leukemia(2nd ed).Elsevier,New York,1990
 
9)Heim S,Mitelman F:10.Malignant lymphoma.In:Cancer Cytogenetics(2nd ed),Wiley-Liss,New York,1995
 
10)古庄敏行,吉田廼弘,阿部達生ほか編:臨床染色体診断法.金原出版,東京,1996
 
11)阿部達生編著:造血器腫瘍アトラス-形態,免疫,染色体と遺伝子(改訂第3版).日本医事新報社,東京,2000
 

各論

P.67 掲載の参考文献
1)Harris NL:Principles of the revised European-American Lymphoma Classification (from the International Lymphoma Study Group).Ann Oncol 8(suppl 2):S11-S16, 1997
 
2)Harris NL,Jaffe ES,Diebold J et al:World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissue:report of the Clinical Advisory Committee meeting-Airlie House,Virginia,November 1997.J Clin Oncol 17:3835-3849, 1999
 
3)Harris NL:Mature B-cell neoplasm.Introduction.In:Pathology & Genetics of Tumours of Haematopoietic and Lymphoid Tissues.World Health Organization Classification of Tumours,ed.by Jaffe ES,Harris NL,Stein H,IARC Press,Lyon,2001,pp. 121-126
 
4)Horning SJ,Rosenberg SA:The natural history of initially untreated low-grade non-Hodgkin's lymphomas.N Engl J Med 311:1471-1475,1984
PubMed
5)Weisenburger DD,Vose JM,Greiner TC et al:Mantle cell lymphoma.A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 64:190-196,2000
 
6)Hiddemann W,Longo DL,Coiffier B et al:Lymphoma classification-The gap between biology and clinical management is closing.Blood 88:4085-4089, 1996
PubMed
7)Martin F, Kearney JF:Marginal-zone B cells.Nat Rev lmmunol 2:323-335,2002
 
8)Capello D,Gaidano G:Molecular pathophysiology of indolent lymphoma.Haematologica 85:195-201,2000
PubMed
P.70 掲載の参考文献
1)Nakamine H,Masih AS,Sanger WG et al:Richter's syndrome with different immunoglobulin light chain types.Molecular and cytogenetic features indicate a common clonal origin.Am J Clin Pathol 97:656-663,1992
 
2)Oscier DG,Thompsett A,Zhu D et al:Differential rates of somatic hypermutation in V(H)genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities.Blood 89:4153-4160,1997
 
P.74 掲載の参考文献
1) Fisher RI, Dahlberg S, Nathwani BN et al:A clinical analysis of two indolent lymphoma entities:mantle cell lymphoma and marginal zone lymphoma (including the mucosa-assoclated lymphoid tissue and monocytold B-cell subcategories. A South-west Oncology Group study. Blood 85:1075-1082, 1995
 
2) Harris NL, Jaffe ES, Diebold J et al:World Health Organization classiffication of neoplastic diseases of the hematopoietic and lymphoid tissue:report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
 
3) Weisenburger DD, Vose JM, Greiner TC et al:Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 64:190-196, 2000
 
4) Wlodarska I, Meeus P, Stul M et al:Variant t(2;11) (p11;q13) associated with the IgK-CCNDI rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma. Leukemia 18:1705-1710, 2004
 
5) Campo E:Mantle cell lymphoma. A paradigm of cell cycle deregulation and genomic instability ALTSG Lymphoma Forum-2004. June 14, 2004, Nagoya (meeting abstract)
 
6) Fang NY, Greiner TC, Weisenburger DD et al:Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci USA 100:5372-5377, 2003
PubMed
P.77 掲載の参考文献
1) Limpens J, Stad R, Vos C et al:Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 85:2528-2536, 1995
PubMed
2) Lennert K, Feller A:In:Histopathology of Non-Hodgkin's Lymphomas (2nd ed). Springer-Verlag, New York, 1992
 
3) Non-Hodgkin's lymphoma pathologic classification project:National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas Summary and description of a Working Formulation for clinical usage Cancer 49:2112-2135, 1982
PubMed
4) Harris NL:Mature B-cell neoplasm. Introduction. In:Pathology & Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours, ed. by Jaffe Es, Harris NL, Stein H, IARC Press Lyon, 2001, pp121-126
 
P.82 掲載の参考文献
1) Isaacson P, Wright DH:Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma Cancer 52:1410-1416, 1983
PubMed
2) Lymphoma study group of Japanese pathologists:The world health organization classification of malignant lymphomas in Japan:Incidence of recently recognized entities. Pathol Int 50:696-702, 2000
 
3) Akagi T, Motegi M, Tamura A et al:A novel gene, MALTI at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18:5785-5794, 1999
 
4) Liu H, Ye H, Dogan A et al:T(11;18) (q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 98:1182-1187, 2001
 
5) Sakugawa ST, Yoshino T, Nakamura S et al:API2-MALTI fusion gene in colorectal lymphoma. Mod Pathol 16:1232-1241, 2003
 
P.84 掲載の参考文献
1) Gorogan TM, Van Camp B, Kyle RA et al:Plasma cell neoplasms. In:World Health Organization Classification Tumours of Haematopoietic and Lymphoid Tissues (3rd ed). ed. by Jaffe ES, Haris NL, Stein H et al, IARC press, Lyon, 2001, pp.142-156
 
2) Alexiou C, Kau RJ, Dietzfelbinger H et al:Extramedullary plasmacytoma:tumor occurrence and therapeutic concepts. Cancer 85:2305-2314, 1999
PubMed
3) Greipp PR, Leong T, Bennett JM et al:Plasmablastic morphologyan independent prognostic factor with clinical and laboratory correlates:Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 91:2501-2507, 1998
PubMed
P.90 掲載の参考文献
1) Harris NL, Jaffe ES, Diebold J et al:World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
PubMed
2) The Non-Hodgkin's Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
 
3) Almasri NM, Duque RE, Iturraspe J et al:Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 40:259-263, 1992
PubMed
4) Dohner H, Stilgenbauer S, Benner A et al:Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
PubMed
5) Novak U, Oppliger Leibundgut E, Hager J et al:A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:1787-1794, 2002
 
6) Hamblin TJ, Davis Z, Gardiner A et al:Unmutated IgVH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999
 
7) Damle RN, Wasil T, Fais F et al:IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999
 
8) Kruber A, Seiler T, Benner A et al:VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410-1416, 2002
 
9) Oscier DG, Gardiner AC, Mould SJ et al:Multivariate analysis of prognostic factors in CLL:clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100:1177-1184, 2002
PubMed
10) Lin K, Sherrington PD, Dennis M et al:Relationship between p53 dysfunction, CD38 expression, and IgVH mutation in chronic lymphocytic leukemia. Blood 100:1404-1409, 2002
PubMed
11) Jelinek DE Tschumper RC, Geyer SM et al:Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 115:854-861, 2001
 
12) Vilpo J, Tobin G, Hulkkonen J et al:Surface antigen expression and correlation with variable heavy-chain gene mutation status in chronic lymphocytic leukemia. Eur J Haematol 70:53-59, 2003
PubMed
13) Ghia P, Guida G, Stella S et al:The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 101:1262-1269, 2003
PubMed
14) Hamblin TJ, Orchard JA, Ibbotson RE et al:CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023-1029, 2002
PubMed
15) Deaglio S, Capobianco A, Bergui L et al:CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 102:2146-2155, 2003
 
16) Rosenwald A, Alizadeh AA, Widhopf G et al:Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194:1639-1647, 2001
 
17) Chen L, Widhopf G, Huynh L et al:Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100:4609-4614, 2002
PubMed
18) Wiestner A, Rosenwald A, Barry TS et al:ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101:4944-4951, 2003
PubMed
19) Durig J, Nuckel H, Cremer M et al:ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 17:2426-2434, 2003
PubMed
20) Crespo M, Bosch F, Villamor N et al:ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775, 2003
PubMed
21) Orchard JA, Ibbotson RE, Davis Z et al:ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363:105-111, 2004
PubMed
22) Fais F, Ghiotto F, Hashimoto S et al:Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 102:1515-1525, 1998
PubMed
23) Johnson TA, Rassenti Lz, Kipps TJ:Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 158:235-246, 1997
 
24) Hashimoto S, Dono M, Wakai M et al:Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells. J Exp Med 181:1507-1517, 1995
PubMed
25) Oscier DG, Thompsett A, Zhu D et al:Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 89:4153-4160, 1997
 
26) Hamblin TJ, Davis Z, Gardiner A et al:Unmutated, IgVH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999
 
27) 青木定夫:CLLの病態と予後に関する最近の知見. 血液腫瘍科 46:446-454, 2004
 
28) Chiorazzi N, Ferrarini M:B cell chronic lymphocytic leukemia:lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 21:841-894, 2003
 
29) Cheson BD, Bennett JM, Rai KR et al:Guidelines for clinical protocols for chronic lymphocytic leukemia:recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 29:152-163, 1988
 
30)Kipps TJ:Chronic lymphocytic leukemia. Curr Opin Hematol 7:223-234, 2000
PubMed
31)Huh YO, Keating MJ, Saffer HL et al:High levels of surface CD20 expression on circulating lymnphocytes compared withbone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin , Pathol 116:437-443, 2001
 
32)Berinstein NL, Grillo-Lopez AJ, White CA et al:Association of serum Rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9:995-1001, 1988
PubMed
33)Manshouri T, Do KA, Wang X et al:Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101:2507-2513, 2003
PubMed
34) Golay J, Zaffaroni L, Vaccari T et al:Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximabin vitro:CD55 and CD59 regulate complement-mediated celllysis. Blood 95:3900-3908, 2000
 
35) Golay J,Lazzari M,Facchinetti V et al:CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia:further regulation by CD55 and CD59.Blood 98:3383-3389,2001
PubMed
36) Byrd JC, Peterson BL, Morrison VA et al:Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia:results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003
 
37) Savage DG, Cohen NS, Hesdorffer CS et al:Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 44:477-481, 2003
PubMed
38) Brito-Babapulle V, Garcia-Marco J, Maljaie SH et al:The impact of molecular cytogenetics on chronic lymphoid leukaemia. Acta Haematol 98:175-186, 1997
PubMed
39) Basso K, Liso A, Tiacci E et al:Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 199:59-68, 2004
PubMed
P.102 掲載の参考文献
1) Kadin ME, Berard CW, Nanba K et al:Lymphoproliferative disease in Japan and Western countries. Hum Pathol 14:745-772, 1983
PubMed
2) Kondo E, Ogura M, Kagami Y et al:Assessment of prognostic factors in follicular lymphoma patients. Int J Hematol 73:363-368, 2001
PubMed
3) Katsumata N, Matsuno Y, Nakayama H et al:Prognostic factors and a predictive model of follicular lymphoma:a25-year study at a single institution in Japan. Jpn J Clin Oncol 26:445-454, 1996
 
4) The Non-Hodgkin's Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
 
5) Shipp MA, Mauch PM, Harris NL et al:Non-Hodgkin's lymphomas. In:Cancer Principles & Practice Of Oncology, 5th edition, ed. by DeVita VT, Hellman S, Rosenberg SA, Lippincott-Raven, Philadelphia, 1997, pp. 2165-2220
 
6) Horning SJ:Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20 (5 suppl 5):S75-S88, 1993
 
7) Rosenberg SA:Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas:challenges and opportunities. J Clin Oncol 3:299-310, 1985
PubMed
8) Oviatt DL, Cousar JB, Collins RD et al:Malignant lymphomas of follicular center cell origin in humans. V. Incidence, clinical features, and prognostic implications of transformation of small cleaved cell nodular lymphoma. Cancer 53:1109-1114, 1984
PubMed
9) Chen PM, Lim SH, Seto M et al:Rearrangement of bcl-2 genes in malignant lymphomas in Chinese patients. Cancer 72:3701-3706, 1993
 
10) 中村栄男:A. 非ホジキンリンパ腫[1]B細胞a. 普遍的な型3濾胞性リンパ腫. 新・悪性リンパ腫アトラス, 須知泰山, 菊池昌弘編, 文光堂, 東京, 2000, pp. 59-67
 
11) Yasukawa M, Bando S, Dolken G et al:Low frequency of BCL-2/J (H) translocation in peripheral blood lymphocytes of healthy Japanese individuals. Blood 99:486-488, 2001
 
12) The Non-Hodgkin's Lymphoma Pathologic Classification Project:National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas:summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
PubMed
13) Harris NL, Jaffe ES, Stein H et al:A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
 
14) Jaffe ES, Harris NL, Stein H et al (ed):In:World Health Organization Classification of Tumors. Pathology & Genetics. Tumor of Hematopoietic and Lymophoid Tissues, IARC Press, Lyon, 2001
 
15) Ngan BY, Chen-Levy Z, Weiss LM et al:Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med 318:1638-1644, 1988
 
16) Hiddemann W, Longo DL, Coiffier B et al:Lymphoma classification-the gap between biology and clinical management is closing. Blood 88:4085-4089, 1996
PubMed
17) Anderson JR, Vose JM, Bierman PJ et al:Clinical features and prognosis of follicular large-cell lymphoma:a report from the Nebraska Lymphoma Study Group. J Clin Oncol 11:218-224, 1993
 
18) Bartlett NL, Rizeq M, Dorfman RF et al:Follicular large-cell lymphoma:intermediate or low grade? J Clin Oncol 12:1349-1357, 1994
PubMed
19) Rodriguez J, McLaughlin P, Hagemeister FB et al:Follicular large cell lymphoma:an aggressive lymphoma that often presents with favorable prognostic features. Blood 93:2202-2207, 1999
PubMed
20) Longo DL:What's the deal with follicular lymphomas? J Clin Oncol 11:202-208, 1993
PubMed
21) Mac Manus MP, Hoppe RT:Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282-1290, 1996
 
22) Wilder RB, Jones D, Tucker SL et al:Long term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 51:1219-1227, 2001
 
23) McLaughlin P, Fuller LM, Velasquez WS et al:Stage I-II follicular lylnphoma. Treatment results for 76 patients. Cancer 58:1596-1602, 1986
 
24) Seymour JF, pro B, Fuller LM et al:Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 21:2115-2122, 2003
 
25) Lopez-Guillermo A, Montserrat E, Bosch F et al:Applicability of the International Index for aggressive lymphomas topatients with low-grade lymphoma. J Clin Oncol 12:1343-1348, 1994
 
26) Decaudin D, Lepage E, Brousse N et al:Low-grade stage III-IV follicular lymphoma:multivariate analysis of prognostic factors in 484 patients-a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 17:2499-2505, 1999
 
27) Federico M, Vitolo U, Zinzani PL et al:Prognosis of follicular lymphoma:a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 95:783-789, 2000
PubMed
28) Colombat P, Solal-Celigny P, Roy P et al:Validity of the Follicular Lymphoma International Prognostic Index (FLIPI) in all age groups. Blood 100:770a, 2002 (abstr)
 
29) Horning SJ, Rosenberg SA:The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Eng J Med 311:1471-1475, 1984
 
30) Young RC, Longo DL, Glatstein E et al:The treatment of indolent lymphomas:watchful waiting v aggressive combined modality treatment. Semin Hematol 25 (2 suppl 2):S11-S16, 1988
 
31) Dana BW, Dahlberg S, Nathwani BN et al:Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993
PubMed
32) Peterson BA, Petroni GR, Frizzera G et al:Prolonged single-agent versus combination chemotherapy in indolent follicularlymphomas:a study of the cancer and leukemia group B. J Clin Oncol 21:5-15, 2003
 
33) Vigliotti ML, D'Arena G, Dell'Olid M et al:Fludarabine-based regimen in follicular NHL (FL):Better survival compared with historical control group. Blood 100:299b, 2002 (abstr)
 
34) Solal-Celigny P, Brice P, Brousse N et al:Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma:a multicenter study by the Group d'Etude des Lymphomes l'Adulte. J Clin Oncol 14:514-519, 1996
 
35) McLaughlin P, Hagenmeister FB, Romaguera JE et al:Fludarabin, mitoxantrone, and dexamethasone:an effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268, 1996
 
36) Hochster HS, Oken MM, Winter JN et al:Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma:results and long-term follow-up-a report from the Eastern Cooperative Oncology Group. J Clin Oncol 18:987-994, 2000
 
37) Foon KA, Scherwin SA, Abrams PG et al:Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 311:1148-1152, 1984
 
38) Fisher RI, Dana BW LeBlanc M et al:Interferon alpha consolidation after intensive chemotherapy dose not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma:results of the Southwest Oncology Group randmized phase II study 8809. J Clin Oncol 18:2010-2016, 2000
 
39) Reff ME, Carner K, Chambers KS et al:Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
PubMed
40) Demidem A, Lam T, Alas S et al:Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radio-pharm 12:177-186, 1997
 
41) Maloney DG, Smith B, Appelbaum FR:The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood 88:637a, 1996 (abstr)
 
42) Tedder TF, Engel P:CD20:a regulator of cell-cycle progres-sion of B lymphocytes. lmmunol Today l5:450-454, 1994
 
43) Foran JM, Rohatiner Az, Cunningham D et al:European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
 
44) Maloney DG, Liles TM, Czerwinski DK et al:Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466, 1994
PubMed
45) Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al:IDEC-C2B8:results of phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274, 1997
PubMed
46) Maloney DG, Grillo-Lopez AJ, White CA et al:IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
PubMed
47) Piro LD, White CA, Grillo-Lopez AJ et al:Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10:655-661, 1999
 
48) Tobinai K, Kobayashi Y, Narabayasi M et al:Feasibility and pharmacokinetic study of a chimeric ant-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 9:527-534, 1998
 
49) Tobinai K, Kobayashi Y, Ohtsu T et al:Phase II study of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, Rituxi-mab) in relapsed indolent B-cell Lymphoma. Ann Oncol 10 (suppl 3):S133, 1999 (abstr)
 
50) Mclaughlin P, Grillo-Lopez AJ, Link BK et al:Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
 
51) Foran JM, Gupta RK, Cunningham D et al:A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonalantibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 109:81-88, 1999
 
52) Hainsworth JD, Burris HA 3rd, Morrissey LH et al:Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95:3052-3056, 2000
PubMed
53) Davis TA, Grillo-Lopez AJ, white CA et al:Rituximab anti-CD-20 monoclonal antibody therapy in non-Hodgkin's lymphoma:safety and efficacy of re-treatment. J Clin Oncol l8:3135-3143, 2000
 
54) Czuczman MS, Grillo-Lopez AJ, white CA et al:Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
PubMed
55) Mounier N, Briere J, Gisselbrecht C et al:Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279-4284, 2003
 
56) Kerst JM, de Haas M, van der Schoot CE et al:Recombinant granulocyte colony-stimulating factor administration to healthy volunteers:induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood 82:3265-3267, 1993
PubMed
57) Niitsu N, Hayama M, Okamoto M et al:Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma. Clin Cancer Res 10:4077-4082, 2004
PubMed
58) van der Kolk LE, Grillo-Lopez AJ, Baars JW et al:Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF:final report on safety and efficacy. Leukemia 17:1658-1664, 2003
 
59) Davis TA, Maloney DG, Grillo-Lopez AJ et al:Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α-2a. Clin Cancer Res 6:2644-2652, 2000
 
60) Buckstein R, Imrine K, Potichnyj A et al:Stem cell functionand engraftment is not affected by"in vivo purging"with rituximab for autologous stem cell treatment for patients with lowgrade non Hodgkin's lymphoma. Semin Oncol 26 (5 suppl 14):S115-S122, 1999
 
61) 岡本昌隆:造血幹細胞移植の適応. 臨床血液 42:299-306, 2001
 
62) Freedman AS, Neuberg D, Mauch P et al:Long-term followup of autologous bone marrow transplantation in patients withrelapsed follicular lymphoma. Blood 94:3325-3333, 1999
PubMed
63) Bierman PJ, Vose JM, Anderson JR et al:High-dose therapyand autologous hematopoietic rescue for follicular low-gradenon-Hodgkin's lymphoma. J Clin Oncol 15:445-450, 1997
 
64) Williams CD, Goldstone AH, Pearce RM et al:Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma:a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 14:2454-2464, 1996
PubMed
65) Magni M, Di Nicola M, Devizzi L et al:Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma:evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869, 2000
PubMed
66) Freedman AS, Gribben JG, Neuberg D et al:High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780-2786, 1996
PubMed
67) Fouillard L, Laporte Jp, Labopin M et al:Autologous stem-cell transplantation for non-Hodgkin's lymphomas:the role of graft purging and radiotherapy posttransplantation-results of aretrospective analysis on 120 patients autografted in a single institution. J Clin Oncol 16:2803-2816, 1998
 
68) van Besien K, Sobocinski KA, Rowlings PA, et al:Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832-1836, 1998
PubMed
69) Archuleta TD, Armitage JO:Advances in follicular lymphoma. Semin Oncol 31 (2 suppl 4):S66-S71, 2004
 
P.108 掲載の参考文献
1) Isaacson P, Wright DH:Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 52:1410-1416, 1983
PubMed
2) Tumours of Haematopoietic and Lymphoid Tissues:In:World Health Organization Classification of Tumours. ed. by Jaffe ES, Harris NL, Stein H et al, IARC Press, Lyon, 2001
 
3) Lymphoma Study Group of Japanese Pathologists:The world health organization classification of malignant lymphomas in Japan:incidence of recently recognized entities. Pathol Int 50:696-702, 2000
 
4) Isaacson PG, Berger E Muller-Hermelink HK et al:Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In:Tumours of Haematopoietic and Lymphoid Tissues:World Health Organization Classification of Tumours, ed. by Jaffe ES, Harris NL, Stein H et al, IARC Press, Lyon, 2001, pp. 157-160
 
5) Eidt S, Stolte M, Fischer R:Helicobacter pylori gastritis and primary gastric non-Hodgkin's lymphomas. J Clin Pathol 47:436-439, 1994
PubMed
6) Thieblemont C, Berger F, Dumontet C et al:Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95:802-806, 2000 (Erratum in:Blood 95:2481, 2000)
 
7) 中村常哉, 中村栄男:MALT-type lymphomaの内視鏡像と病理診断の現況. Gastroenterol Endosc 42:1163-1175, 2000
 
8) Ott G, Katzenberger T, Greiner A et al:The t(11;18) (q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of mucosa-associated lymphoid tissue (MALT) type. Cancer Res 57:3944-3948, 1997
 
9) Akagi T, Motegi M, Tamura A et al:A novel gene, MALTI at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18:5785-5794, 1999
 
10) Yonezumi M, Suzuki R, Suzuki H et al:Detection of AP12-MALTI chimaeric gene in extranodal and nodal marginal zone B-cell lymphoma by reverse transcription polymerase chain reaction (PCR) and genomic long and accurate PCR analysis. Br J Haematol 115:588-594, 2001
 
11) Ye H, Liu H, Attygalle A et al:Variable frequencies of t(11;18) (q21;q21) in MALT lymphomas of different sites:significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood 102:1012-1018, 2003
PubMed
12) Streubel B, Lamprecht A, Dierlamm J et al:T(14;18) (q32;q21) involving IgH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101:2335-2339, 2003
PubMed
13) Willis TG, Jadayel DM, Du MQ et al:Bcl10 is involved in t(1;14) (p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96:35-45, 1999
 
14) Wotherspoon AC, Doglioni C, Diss TC et al:Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342:575-577, 1993
PubMed
15) Neubauer A, Thiede C, Morgner A et al:Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 89:1350-1355, 1997
PubMed
16) Thiede C, Wundisch T, Neubauer B et al:Eradication of Helicobacter pylori and stability of remissions in low-grade gastric B-cell lymphomas of the mucosa-associated lymphoid tissue:results of an ongoing multicenter trial. Recent Results Cancer Res 156:125-133, 2000
PubMed
17) 日本ヘリコバクター学会ガイドライン作成委員会:H.pylori感染の診断と治療のガイドライン2003年度改訂版. 日本ヘリコバクター学会誌 4 (suppl):S2-S17, 2003
 
18) Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A et al:Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 357:39-40, 2001
PubMed
19) Nakamura T, Nakamura S, Yokoi T et al:Clinicopathologic comparison between the API2-MALT1 chimeric transcript-positive and-negative gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type. Jpn J Cancer Res 93:677-684, 2002
PubMed
20) Rohatiner A, d'Amore F, Coiffier B et al:Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 5:397-400, 1994
PubMed
21) Schechter NR, Portlock CS, Yahalom J:Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 16:1916-1921, 1998
PubMed
22) Fisher RI, Dahlberg S, Nathwani BN et al:A clinical analysis of two indolent lymphoma entities:mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories):a Southwest Oncology Group study. Blood 85:1075-1082, 1995
 
23) Conconi A, Martinelli G, Thieblemont C et al:Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 102:2741-2745, 2003
PubMed
P.114 掲載の参考文献
1) Bosch F, Lopez-Guillermo A, Campo E et al:Mantle cell lymphoma:presenting features, response to therapy, and prognostic factors. Cancer 82:567-575, 1998
PubMed
2) Lenz G, Dreyling M, Hiddemann W:Mantle cell lymphoma:established therapeutic options and future directions. Ann Hematol 83:71-77, 2004
PubMed
3) Majilis A, Pugh WC, Rodriguez MA et al:Mantle cell lymphoma:correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 15:1664-1671, 1997
 
4) Oinonen R, Franssila K, Elonen E:Central nervous system involvement in patients with mantle cell lymphoma. Ann, Hematol 78:145-149, 1999
PubMed
5) Andersen NS, Jensen MK, de Nully Brown P et al:A Danish population-based analysis of 105 mantle cell lymphoma patients:incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 38:401-408, 2002
PubMed
6) Greiner TC, Moynihan MJ, Chan WC et al:p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87:4302-4310, 1996
PubMed
7) Niitsu N, Okamoto M, Okabe-Kado J et al:Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphoma. Leukemia 15:832-839, 2001
PubMed
8) Fisher RI, Dahlberg S, Nathwani BN et al:A clinical analysis of two indolent lymphoma entities:mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories):a South-west Oncology Group study. Blood 85:1075-1082, 1995
 
9) Meusers P, Engelhard M, Bartels H et al:Multicentre randomized therapeutic trial for advanced centrocytic lymphoma:anthracycline does not improve the prognosis. Hematol Oncol 7:365-380, 1989
 
10) Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al:Efficacy of four different regimens in 64 mantle-cell lymphoma cases:clinicopathologic comparison with 498 0ther non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 13:2819-2826, 1995
 
11) Hiddemann W, Unterhalt M, Herrmann R et al:Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas:results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 16:1922-1930, 1998
 
12) Zucca E, Roggero E, Pinotti G et al:Patterns of survival in mantle cell lymphoma. Ann Oncol 6:257-262, 1995
PubMed
13) Decaudin D, Bosq J, Tertian G et al:Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 16:579-583, 1998
PubMed
14) Foran JM, Rohatiner AZ, Coiffier B et al:Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17:546-553, 1999
PubMed
15) Cohen BJ, Moskowitz C, Straus D et al:Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 42:1015-1022, 2001
PubMed
16) Zinzani PL, Magagnoli M, Moretti L et al:Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J clin Oncol 18:773-779, 2000
PubMed
17) Rummel MJ, Chow KU, Jager E et al:Intermittent 2-hour-irfusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. Leuk Lymphoma 35:129-138, 1999
 
18) Rummel MJ, Chow KU, Karakas T et al:Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. Eur J Cancer 38:1739-1746, 2002
PubMed
19) Foran JM, Rohatiner Az, Cunningham D et al:European phase II study of rituximab (chimeric anti-CD20 monoclonal anti-body) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
 
20) Ghielmini M, Schmitz SF, Burki K et al:The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 11:123-126, 2000
 
21) Howard OM, Gribben JG, Neuberg DS et al:Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma:molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20:1288-1294, 2002
 
22) Levine A, Espina BM, Mohrbacher A et al:Fludarabine, Mitoxantrone and Rituxan:An Effective Regimen for the Treatment of Mantle Cell Lymphoma. Blood 2002; #1399
 
23) Rorstpointner R, Dreyling M, Repp R et al:The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004
 
24) Khouri IF, Romaguera J, Kantarjian H et al:Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation:an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-3809, 1998
PubMed
25) Freedman AS, Neuberg D, Gribben JG et al:High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purgedautologous bone marrow transplantation in mantle-cell lymphoma:no evidence for long-term remission. J Clin Oncol 16:13-18, 1998
PubMed
26) Gianni AM, Magni M, Martelli M et al:Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102:749-755, 2003
PubMed
27) Khouri IF, Lee MS, Romaguera J et al:Allogeneic hematopoietic transplantation for mantle-cell lymphoma:molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 10:1293-1299, 1999
PubMed
28) Kouroukis CT, Belch A, Crump M et al:Flavopiridol in untreated or relapsed mantle-cell lymphoma:results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:1740-1745, 2003
PubMed
29) O'Connor OA:The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas. Curr Treat Options Oncol 5:269-281, 2004
PubMed
30) Frankel SR:Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia:a targeted approach to enhance apoptosis. Semin Oncol 30:300-304, 2003
PubMed
P.130 掲載の参考文献
1) Tonegawa S:Somatic generation of antibody diversity. Nature 302:575-581, 1983
PubMed
2) MacLennan IC:Germinal centers. Annu Rev Immunol 12:117-139, 1994
PubMed
3) Liu YJ, Malisan F, de Bouteiller O et al:Within germinal centers, isotype switching of immunoglobulin genes occurs after the onset of somatic mutation. Immunity 4:241-250, 1996
PubMed
4) Hikida M, Mori M, Takai T et al:Reexpression of RAG-1 and RAG-2 genes in activated mature mouse B cells. Science 274:2092-2094, 1996
PubMed
5) Kuppers R, Klein U, Hansmann ML et al:Cellular origin of human B-cell lymphomas. N Engl J Med 341:1520-1529, 1999
 
6) Kuppers R, Dalla-Favera R:Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20:5580-5594, 2001
 
7) Nakamura N, Abe M:Histogenesis of CD5-positive and CD5-negative B-cell neoplasms on the aspect of somatic mutation of immunoglobulin heavy chain gene variable region. Fukushima J Med Sci 49:55-67, 2003
PubMed
8) Shen HM, Peters A, Baron B et al:Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 280:1750-1752, 1998
PubMed
9) Pasqualucci L, Neumeister P, Goossens T et al:Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412:341-346, 2001
 
10) Hecht JL, Aster JC:Molecular biology of Burkitt's lymphoma. J Clin Oncol 18:3707-3721, 2000
PubMed
11) Roschke V, Kopantzev E, Dertzbaugh M et al:Chromosomal translocations deregulating c-myc are associated with normal immune responses. Oncogene 14:3011-3016, 1997
PubMed
12) Akasaka T, Akasaka H, Ueda C et al:Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J Clin Oncol 18:510-518, 2000
 
13) Nakamura N, Nakamine H, Tamaru J et al:The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement. Mod Pathol 15:771-776, 2002
 
14) Klein U, Goossens T, Fischer M et al:Somatic hypermutation in normal and transformed human B cells. Immunol Rev 162:261-280, 1998
 
15) Jaffe ES, Wilson WH:Lymphomatoid granulomatosis:pathogenesis, pathology and clinical implications. Cancer Surv 30:233-248, 1997
PubMed
16) Delecluse HJ, Anagnostopoulos I, Dallenbach F et al:Plasmablastic lymphomas of the oral cavity:a new entity associated with the human immunodeficiency virus infection. Blood 89:1413-1420, 1997
PubMed
17) Abou-Elella AA, Weisenburger DD, Vose JM et al:Primary mediastinal large B-cell lymphoma:a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol 17:784-790, 1999
 
18) Nador RG, Cesarman E, Chadburn A et al:Primary effusion lymphoma:a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 88:645-656, 1996
PubMed
19) Glass J, Hochberg FH, Miller DC:Intravascular lymphomatosis. A systemic disease with neurologic manifestations. Cancer 71:3156-3164, 1993
PubMed
20) Aozasa K, Ohsawa M, Iuchi K et al:Artificial pneumothorax as a risk factor for development of pleural lymphoma. Jpn J Cancer Res 84:55-57, 1993
PubMed
21) 0yama T, Ichimura K, Suzuki R et al:Senile EBV+ B-cell lymphoproliferative disorders:a clinicopathologic study of 22 patients. Am J Surg Pathol 27:16-26, 2003
 
22) Yamaguchi M, Seto M, Okamoto M et al:De novo CD5+ diffuse large B-cell lymphoma:a clinicopathologic study of 109 patients. Blood 99:815-821, 2002
PubMed
23) Nakamura N, Kuze T, Hashimoto Y et al:Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and-negative diffuse large B cell lymphoma. Leukemia 15:452-457, 2001
PubMed
24) Kobayashi T, Yamaguchi M, Kim S et al:Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5-diffuse large B-cell lymphomas. Cancer Res 63:60-66, 2003
 
25) Hojo H, Kuze T, Nakamura N et al:Analysis of immunoglobulin VH genes in CD10-positive diffuse large B-cell lymphoma. Pathol Int 52:586-594, 2002
PubMed
26) Kuze T, Nakamura N, Hashimoto Y et al:The relationship between the gene mutation of p53 and the protein expressionof p53 and Ki-67 in non-Hodgkin's lymphomas. Pathol Int 46:130-136, 1996
 
27) Alizadeh AA, Eisen MB, Davis RE et al:Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
PubMed
28) Hans CP, Weisenburger DD, Greiner TC et al:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103:275-282, 2004
PubMed
29) Nakamura N, Abe M:Richter syndrome in B-cell chronic lymphocytic leukemia. Pathol lnt 53:195-203, 2003
 
P.140 掲載の参考文献
1) The International Non-Hodgkin's Lymphoma Prognostic Factors Project:A predictive model for aggressive non-Hodgkin's lymphomas. N Engl J Med 329:987-994, 1993
 
2) Steeg PS, Bevilacqua G, Kopper L et al:Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80:200-204, 1988
PubMed
3) Okabe-Kado J, Kasukabe T, Honma Y et al:Purification of a factor inhibiting differentiation from conditioned medium of nondifferentiating mouse myeloid leukemia cells. J Biol Chem 263:10994-10999, 1988
 
4) Fan Z, Beresford PJ, Oh DY et al:Tumor Suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 112:659-672, 2003
PubMed
5) Niitsu N, Okabe-Kado J, Kasukabe T et al:Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 94:3541-3550, 1999
PubMed
6) Niitsu N, Okabe-Kado J, Okamoto M et al:Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood 97:1202-1210, 2001
PubMed
7) Niitsu N, Honma Y, Iijima K et al:Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma. Leukemia 17:196-202, 2003
PubMed
8) Niitsu N, Nakamine H, Okamoto M et al:Clinical significance of intracytoplasmic nm23-Hl expression in diffuse large B-cell lymphoma. Clin Cancer Res 10:2482-2490, 2004
 
9) Alizadeh AA, Eisen MB, Davis RE et al:Distinct type of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
PubMed
10) Lossos IS, Alizadeh AA, Eisen MB et al:Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 97:10209-10213, 2000
 
11) Huang Jz, Sanger WG, Greiner TC et al:The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 99:2285-2290, 2002
 
12) Shipp MA, Ross KN, Tamayo P et al:Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68-74, 2002
PubMed
13) Rosenwald A, Wright G, Chan WC et al:The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
PubMed
14) Lossos IS, Czerwinski DK, Alizadeh AA et al:Prediction ofsurvival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828-1837, 2004
 
15) Miller TP, Dahlberg S, Cassady JR et al:Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998
PubMed
16) Miller TP, Leblanc M, Spier C et al:for the Southwest Oncology Group:CHOP Alone Compared to CHOP Plus Radiotherapy for Early Stage Aggressive Non-Hodgkin's Lymphomas:Update of the Southwest Oncology Group (SWOG) Randomized Trial. Blood 98:724 (#3024), 2001
 
17) Horning SJ, Glick JH, Kim K:Final Report of E1484:CHOP v CHOP+Radiotherapy (RT) for Limited Stage Diffuse Aggressive Lymphoma. Blood 98:724 (#3023), 2001
 
18) Fillet G, Bonnet C, Mounier N et al:Radiotherapy Is Unnecessary in Elderly Patients with Localized Aggressive Non Hodgkin's Lymphoma:Results of the GELA LNH 93-4 Study. Blood 99:(#337), 2002
 
19) Coiffier B, Lepage E, Briere J et al:CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
PubMed
20) Fisher RI, Gaynor ER, Dahlberg S et al:Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
PubMed
21) Armitage JO, Weisenburger DD:New approach to classifying non-Hodgkin's lymphomas:clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16:2780-2795, 1998
PubMed
22) Niitsu N, Okamoto M, Kuraishi Y et al:CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma:a pilot study The Adult Lymphoma Treatment Study Group (ALTSG). Eur J Haematol 65:188-194, 2000
 
23) Tilly H, Lepage E, Coiffier B et al:Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289, 2003
 
24) Pfreundschuh M, Trumper L, Kloess M et al:Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:results of the NHl-B2 trial of the DSHNHL. Blood 104:634-641, 2004
 
25) Pfreundschuh M, Trumper L, Kloess M et al:Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas:results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633, 2004
 
P.144 掲載の参考文献
1) Diebold J, Jaffe ES, Raphael M et al:Burkitt lymphoma. In:Tumours of hermatopoietic and Lymphoid Tissues, ed. by Jaffe ES, Harris NL, Stein H et al, IARCPress, Lyon, 2001, pp. 181-184
 
2) The Non-Hodgkin's lymphoma classification project:A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
 
3) Facer CA, Playfair JH:Malaria, Epstein-Barr virus, and the genesis of lymphomas. Adv Cancer. Res 53:33-72, 1989
PubMed
4) Anwar N, Kingma DW Bloch AR et al:The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt's lymphoma from Egypt:epidemiologic correlations. Cancer 76:1245-1252, 1995
PubMed
5) Raphael M, Gentilhomme O, Tulliez M et al:Histopathologic features of high-grade non-Hodgkin's lymphomas in acquired immunodeficiency syndrome. Arch. Pathol. Lab Med 115:15-20, 1991
PubMed
6) Niwano H, Aoki S, Tsukada N et al:An aggressive case of Burkitt's lymphoma with t(8;14) and c-myc rearrangement transformed from CD5+B-cell lymphoma. Ann Hematol 75:221-225, 1997
 
7) Grogan TM:Morphologic, immunologic and genetic features of Burkitt's and Burkitt-like lymphomas. In:Human Lymphoma; Clinical Implications of The Real Classification, ed. by Mason DY, Harris NL, Springer-Verlag, London, 1999, chapter 41
 
8) Garcia JL, Hernandez JM, Gutierrez NC et al:Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study Leukemia 17:2016-2024, 2003
PubMed
9) Magrath IT, Janus C, Edwards BK et al:An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 63:1102-1111, 1984
 
10) Cairo MS, Sposto R, Perkins SL et al:Burkitt's and Burkitt-like lymphoma in children and adolescents:a review of the Children's Cancer Group experience. Br J Haematol 120:660-670, 2003
 
11) Pillon M, Di Tullio MT, Garaventa A et al:Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer 101:385-394, 2004
PubMed
12) Magrath I, Adde M, Shad A et al:Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934, 1996
PubMed
13) Todeschini G, Tecchio C, Degani D et al:Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia:no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol 8 (suppl 1):S77-S81, 1997
 
14) Mead GM, Sydes MR, Walewski J et al:An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma:results of United Kingdom Lymphoma Group LYO6 study. Ann Oncol 13:1264-1274, 2002
PubMed
15) Wang ES, Straus DJ, Teruya-Feldstein J et al:Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 98:1196-1205, 2003
PubMed
16) Lacasce A, Howard O, Lib S et al:Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas:preserved efficacy with decreased toxicity Leuk Lymphoma 45:761-767, 2004
PubMed
17) de Vries MJ, Veerman AJ, Zwaan CM et al:Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin's lymphoma. Br J Haematol 125:414-415, 2004
PubMed
18) Johnson TA, Press OW:Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. Int J Cancer 85:104-112, 2000
PubMed
19) Thomas DA, Cortes J, O'Brien S et al:Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461-2470, 1999
 
P.149 掲載の参考文献
1) Brunning RD, Flandrin G, Borowitz M et al:Precursor B lymphoblastic leukemia/lymphoblastic lymphoma (Precursor B-cell acute lymphoblastic leukaemia). In:Tumours of Haematopoietic and Lymphoid Tissues/World Health Organization Classification of Tumours, ed. by Jaffe ES, Harris NL, Stein H et al, IARC Press, Lyon, 2001, pp. 111-114
 
2) Brunning RD, Flandrin G, Borowitz M et al:Precursor T lymphoblastic leukemia/lymphoblastic lymphoma (Precursor T-cell acute lymphoblastic leukaemia). In:Tumours of Haematopoietic and Lymphoid Tissues/World Health Organization Classification of Tumours, ed. by Jaffe ES, Harris NL, Stein H et al, IARC Press, Lyon, 2001, pp. 115-117
 
3) Murphy SB:Childhood non-Hodgkin's lymphoma. N Engl J Med 299:1446-1448, 1978
PubMed
4) Thomas D, Kantarjian H:Lymphoblastic lymphoma. In:Hematology/Oncology Clinics of North America:Advances in the Treatment of Adult Leukemia, Part II, Vol 15, ed. by Kantarjian H, Hoelzer D, Larson R, W B. Saunders, Philadelphia, 2001, pp. 51-95
 
5) Sandlund JT, Magrath IT:Lymphoblastic lymphoma. In:The Non-Hodgkin's Lymphoma (2nd ed), ed. by Magrath IT, Arnold, London, 1997, pp. 813-828
 
6) Coleman CN, Picozzi VJ Jr, Cox RS et al:Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 4:1628-1637, 1986
PubMed
7) Picozzi VJ Jr, Coleman CN:Lymphoblastic lymphoma. Semin Oncol 17:96-103, 1990
PubMed
8) Quintanilla-Martinez L, Zukerberg LR, Harris NL:Prethymic adult lymphoblastic lymphoma:A clinicopathologic and immunohistochemical analysis. Am J Surg Pathol 16:1075-1084, 1992
PubMed
9) The non-Hodgkin's lymphoma pathologic classification project:The National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas. Cancer 49:2112-2135, 1982
 
10) Streuli RA, Kaneko Y, Variakojis D et al:Lymphoblastic lymphoma in adults. Cancer 47:2510-2516, 1981
PubMed
11) Soslow RA, Baergen RN, Warnke RA:B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer 85:2648-2654, 1999
PubMed
12) Lin P, Jones D, Dorfman DM et al:Precursor B-cell lymphoblastic lymphoma:a predominantly extranodal tumor with low propensity for leukemic involvement. Am J Surg Pathol 24:1480-1490, 2000
PubMed
13) Maitra A, McKenna RW, Weinberg AG et al:Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature. Am J Clin Pathol 115:868-875, 2001
PubMed
14) Kaneko Y, Frizzera G, Shikano T et al:Chromosomal and immunophenotypic patterns in T cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL). Leukemia 3:886-892, 1989
 
15) Kaneko Y, Frizzera G, Maseki N et al:A novel translocation, t(9;17) (q34;q23), in aggressive childhood lymphoblasticlymphoma. Leukemia 2:745-748, 1988
PubMed
16) Nathwani BN, Diamond LW, Winberg CD et al:Lymphoblastic lymphoma:a clinicopathologic study of 95 patients. Cancer 48:2347-2357, 1981
PubMed
17) Le Gouill S, Lepretre S, Briere J et al:Adult lymphoblastic lympholna:a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials. Leukemia 17:2220-2224, 2003
PubMed
18) Bernasconi C, Brusamolino E, Lazzarino M et al:Lymphoblastic lymphoma in adult patients:clinicopathological features and response to intensive multiagent chemotherapy analogous to that used in acute lymphoblastic leukemia. Ann Oncol 1:141-146, 1990
PubMed
19) Morel P, Lepage E, Brice P et al:Prognosis and treatment oflymphoblastic lymphoma in adults:a report on 80 patients. J Clin Oncol 10:1078-1085, 1992
PubMed
20) Zinzani PL, Bendandi M, Visani G et al:Adult lymphoblastic lymphoma:clinical features and prognostic factors in 53 patients. Leukemia Lymphoma 23:577-582, 1996
PubMed
21) Bouabdallah R, Xerri L, Bardou VJ et al:Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma:a report on 62 patients from a single center. Ann Oncol 9:619-625, 1998
PubMed
22) Hoelzer D, Gokbuget N, Digel W et al:0utcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 99:4379-4385, 2002
 
23) Thomas DA, O'Brien S, Cortes J et al:Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104:1624-1630, 2004
PubMed
24) Kantarjian HM, O'Brien S, Smith TL et al:Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18:547-561, 2000
PubMed
25) Chopra R, Goldstone AH, Pearce R et al:Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma:a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 10:1690-1695, 1992
PubMed
26) De Witte T, Awwad B, Boezeman J et al:Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission. Bone Marrow Transplant 14:767-774, 1994
 
27) Sweetenham JW, Santini G, Qian W et al:High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma:results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19:2927-2936, 2001
 
28) Levine JE, Harris RE, Loberiza FR Jr et al:A comparison of allogeneic and autologous bone marrow transplantation for lym-phoblastic lymphoma. Blood 101:2476-2482, 2003
 
P.153 掲載の参考文献
1) Lymphoma study group of Japanese pathologists:The World Health Organization classification of malignant lymphomas in Japan:incidence of recently recognized entities. Pathol Int 50:696-702, 2000
 
2) Anderson JR, Armitage JO, Weisenburger DD:Epidemiology of the non-Hodgkin's lymphomas:distributions of the major subtypes differ by geographic locations. Ann Oncol 9:717-720, 1998
PubMed
3) Ichimura K, Kagami Y, Suzuki R et al:Phenotypic analysis of peripheral T/NK cell lymphoma:Study of 408 Japanese cases with special reference to their anatomical sites. Pathol lnt 53:333-344, 2003
 
4) Tsuchiya T, Ohshima K, Karube K et al:Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified:comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood 103:236-241, 2004
PubMed
5) Mori N, Krensky AM, Ohshima K et al:Elevated expression of CCL5/RANTES in adult T-cell leukemia cells:possible transactivation of the CCL5 gene by human T-cell leukemia virus type I tax. Int J Cancer 111:548-557, 2004
PubMed
6) Ohshima K, Karube K, Kawano R et al:Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression:Analysis of prognosis. Int J Oncol 25:605-613, 2004
PubMed
7) Jaffe ES, Harris NL, Stein H et al:In:World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Hematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2001
 
P.166 掲載の参考文献
1) Chan JKC, Jaffe ES, Ralfkiaer E:Blastic NK-cell lymphoma. In:VVorld Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, ed. by Jaffe ES, Harris NL, Stein H et al, IARC Press, Lyon, 2001, pp. 214-215
 
2) Kameoka J, Ichinohasama R, Tanaka M et al:A cutaneous agranular CD2-CD4+CD56+ "lymphoma":report of two cases and review of the literature. Am J Clin Pathol 11O:478-488, 1998
 
3) Petrella T, Dalac S, Maynadie M et al:CD4+CD56v cutaneous neoplasms:a distinct hematological entity? Groupe Francais d'Etude des Lymphomes Cutanes (GFELC). Am J Surg Pathol 23:137-146, 1999
PubMed
4) Petrella T, Comeau MR, Maynadie M et al:`Agranular CD4+ CD56+ hematodermic neoplasm:(blastic NK-cell lymphoma) originates from a population of CD56+precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 26:852-862, 2002
PubMed
5) Jacob MC, Chaperot L, Mossuz P et al:CD4+CD56+ lineage negative malignancies:a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica 88:941-955, 2003
PubMed
6) Karube K, Ohshima K, Tsuchiya T et al:Non-B, non-T neo-plasms with lymphoblast morphology:further clarification and classification. Am J Surg Pathol 27:1366-1374, 2003
 
7) Suzuki R, Suzumiya J, Nakamura S et al:Both CD4-positive and CD4-negative subtypes of lastic natural killer cell lymphoma constitute distinct disease entities. Blood 102:630a, 2003
 
P.169 掲載の参考文献
1) Willemze R, Kerl H, Sterry W et al:EORTC CIassification for Primary Cutaneous Lymphomas:A Proposal From the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-371, 1997
 
2) Bekkenk MW, Geelen FA, van Voorst Vader PC et al:Primary and secondary cutaneous CD30+ lymphoproliferative disorders:a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653-3661, 2000
 
P.173 掲載の参考文献
1) Lennert K, Feller AC:In:Histopathology of Non-Hodgkin's Lymphoma ( Based on the Updated. Kiel Classification ). Springer-Verlag, Berlin, 1992
 
2) Yamashita Y, Nakamura S, Kagami Y et al:Lennert's Lymphoma:a variant of cytotoxic T-cell lymphoma? Am J Surg. Pathol 24:1627-1633, 2000
 
P.174 掲載の参考文献
1) Suzuki K, Ohshima K, Karube K et al:Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults. Int J Oncol 24:1165-1174, 2004
 
P.181 掲載の参考文献
1) Armitage JO, Weisenburger DD:New approach to classifying non-Hodgkin's lymphomas:clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16:2780-2795, 1998
PubMed
2) Gisselbrecht C, Gaulard P, Lepage E et al:Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 92:76-82, 1998
PubMed
3) Gallamini A, Stelitano C, Calvi R et al:Peripheral T-cell lymphoma unspecified (PTCL-U):a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004
 
4) Niitsu N, Nakamine H, Okamoto M et al:Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma. Br J Haematol 123:621-630, 2003
PubMed
5) Falini B, Pileri S, Zinzani PL et al:ALK+lymphoma:clinico-pathological findings and outcome. Blood 93:2697-2706, 1999
PubMed
6) Stein H, Foss HD, Durkop H et al:CD30 (+) anaplastic large cell lymphoma:a review of its histopathologic, genetic, and clinical features. Blood 96:3681-3695, 2000
PubMed
7) Siegert W, Nerl C, Agthe A et al:Angioimmunoblastic lympha-denopathy (AILD)-type T-cell lymphoma:prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol 6:659-664, 1995
 
8) Pangalis GA, Moran EM, Rappaport H:Blood and bone marrow findings in angioimmunoblastic lymphadenopathy. Blood 51:71-83, 1978
PubMed
9) Siegert W, Agthe A, Griesser H et al:Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 117:364-370, 1992
 
10) Tsatalas C, Margaritis D, Kaloutsi V et al:Successful treatment of angioimmunoblastic lymphadenopathy with dyspro-teinemia-type T-cell lymphoma with fludarabine. Acta. Haematol 105:106-108, 2001
 
11) Strupp C, Aivado M, Germing U et al:Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment:two case reports. Leuk Lymphoma 43:133-137, 2002
PubMed
12) Tsimberidou AM, Giles F, Duvic M:Phase II study of pentostatin in advanced T-cell lymphoid malignancies:update of an M. D. Anderson Cancer Center series. Cancer 100:342-349, 2004
 
13) Sallah S, Wan JY, Nguyen NP:Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 113:185-187, 2001
PubMed
14) Talpur R, Apisarnthanarax N, Ward S et al:Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk Lymphoma 43:121-126, 2002
PubMed
15) Huang CL, Lin ZZ, Su IJ et al:Combination of 13-cis retinoic acid and interferon-alpha in the treatment of recurrent or refractory peripheral T-cell lymphoma. Leuk Lymphoma 43:1415-1420, 2002
PubMed
16) Belhadj K, Reyes F, Farcet Jp et al:Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome:report on a series of 21 patients. Blood 102:4261-4269, 2003
PubMed
17) Weidmann E:Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 14:991-997, 2000
PubMed
18) Niitsu N, Kohri M, Togano T et al:Development of hepatosplenic γδ T-cell lymphoma with pancytopenia during earlypregnancy:A case report and review of the literature. Eur J Haematol 73:367-371, 2004
 
19) Iannitto E, Barbera V, Quintini G et al:Hepatosplenic gammadelta T-cell lymphoma:complete response induced by treatment with pentostatin. Br J Haematol 117:995-996, 2002
PubMed
20) Gale J, Simmonds PD, Mead GM et al:Enteropathy-type intestinal T-cell lymphoma:clinical features and treatment of 31 patients in a single center. J Clin Oncol 18:795-803, 2000
 
P.189 掲載の参考文献
1) Lymphoma Study Group of Japanese Pathologists:The World Health Organization classification of malignant lymphomas in Japan:Incidence of recently recognized entities. Pathol Int 50:696-702, 2000
 
2) Ohshima K, Suzumiya J, Kikuchi M:The World Health Organization classification of malignant lymphoma:incidence and clinical prognosis in HTLV-1 endemic area of Fukuoka. Pathol Int 52:1-12, 2002
PubMed
3) Nakamura S, Suchi T, Koshikawa T et al:Clinicopathologic study of 212 cases of peripheral T-cell lymphoma among the Japanese. Cancer 72:1762-1772, 1993
PubMed
4) Ko YH, Kim CW, Park CS et al:REAL classification of malignant lymphomas in the Republic of Korea:incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 83:806-812, 1998
 
5) Anderson JR, Armitage JO, Weisenburger DD:Epidemiology of the non-Hodgkin's lymphomas:distributions of the major subtypes differ by geographic locations. Ann Oncol 9:717-720, 1998
PubMed
6) Harris NL, Jaffe ES, Stein H et al:A revised European-American classification of lymphoid neoplasms:a proposal from the international lymphoma study group. Blood 84:1361-1392, 1994
 
7) Jaffe ES, Harris NL, Stein H et al:In:World Health Organization Classification of tumors. Pathology & Genetics. Tumors of Hematopoietic and Lymophoid Tissues. IARCPress, Lyon, 2001
 
8) Ho FC, Srivastava G, Loke SL et al:Presence of Epstein-Barr virus DNA in nasal lymphomas of B and T cell type. Hematol Oncol 8:271-281, 1990
 
9) Kobashi Y, Nakamura S, Sasajima Y et al:Inconsistent association of Epstein-Barr virus with CD56 (NCAM)-positive-angiocentric lymphoma occuring in sites other than the upper and lower respiratory tract. Histopathology 28:111-120, 1996
 
10) Chan JKC, Jafe ES, Ralfkiaer E:Extranodal NK/T-cell lymphoma, nasal type. In:World Health Organization Classification of Tumors. Pathology & Genetics. Tumor of Hematopoietic and Lymophoid Tissues, ed. by Jaffe ES, Harris NL, Stein H et al, IARCPress, Lyon, 2001, pp. 204-207
 
11) Chan JKC, WOng KE Jaffe ES et al:Aggressive NK-cellleukemia. In:World Health Organization Classification of Tumors. Pathology & Genetics. Tumor of Hematopoietic and Lymophoid Tissues, ed. by Jaffe ES, Harris NL, Stein H et al, IARCPress, Lyon, 2001, pp. 198-200
 
12) Chan JKC, Jafe ES, Ralfkiaer E:Blastic NK-cell lymphoma. In:World Health Organization Classification of Tumors. Pathology & genetics. Tumor of Hematopoietic and Lymophoid Tissues, ed. by Jaffe ES, Harris NL, Stein H et al, IARCPress, Lyon, 2001, pp. 214-215
 
13) Herling M, Teitell MA, Shen RR et al:TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+CD56+blastic tumors of skin. Blood 101:5007-5009, 2003
PubMed
14) 菊池昌弘, 鈴宮淳司:2. 鼻および鼻型NK細胞リンパ腫. 新・悪性リンパ腫アトラス, 須知泰山, 菊池昌弘編, 文光堂, 東京, 2000, pp. 194-198
 
15) Greer J, Kinney MC, Loughran TP Jr:Tcell and NK cell lymphoproliferative disorders. In:Hematology 2001; American Society of Hematology Education Program Book, ed. by Scgecgter GP, Broudy VC, Williams ME, 2001, pp. 259-281
 
16) 中村栄男, 須知泰山:3. 芽球型NK細胞リンパ腫. 新・悪性リンパ腫アトラス, 須知泰山, 菊池昌弘編, 文光堂, 東京, 2000, pp. 199-203
 
17) Feuillard J, Jacob MC, Valensi F et al:Clinical and biologic features of CD4+CD56+ malignancies. Blood 99:1556-1563, 2002
PubMed
18) Petrella T, Comeau MR, Maynadie M et al:"Agranular CD4+ CD56+hepatodermic neoplasm"(Blastic NK cell lymphoma) originates from a population of CD56+precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 26:852-862, 2002
PubMed
19) Nakamura S, Katoh E, Koshikawa T et al:Clinicopathologic study of nasal T/NK-cell lymphoma among the Japanese. Pathol Int 47:38-53, 1997
PubMed
20) Siu LL, Wong KF, Chan JK et al:Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia:recognition of consistent patterns of genetic alterations. Am J Pathol 155:1419-1425, 1999
PubMed
21) Siu LLP, Chan V, Chan JKC et al:Consistent patterns of allelic loss in natural killer cell lymphoma. Am J pathol 157:1803-1809, 2000
 
22) Cheung MM, Chan JKC, Lau WH et al:Primary non-Hodgkin's lymphoma of the nose and nasopharinx:clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16:70-77, 1998
 
23) Cheung MMC, Chan JKC, WOng KF:Natural killer cell neo-plasms:A distinctive group of highly aggressive lymphomas/ leukemias. Semin Hematol 40:221-232, 2003
 
24) Kim GE, Cho JH, Yang WI et al:Angiocentric lymphoma of the head and neck:patterns of systemic failure after radiation treatment. J Clin Oncol 18:54-63, 2000
PubMed
25) Miller TP, Dahlberg S, Cassady JR et al:Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998
PubMed
26) Kwong YL, Chan ACL, Liang R et al:CD56+NK lymphomas:clinicopathological features and prognosis. Br J Hematol 97:821-829, 1997
 
27) Kim WS, Song Sy, Ahn YC et al:CHOP followed by involved field radiation:is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 12:349-352, 2001
PubMed
28) Cheung MM, Chan JKC, Lau WH et al:Ealry stage nasal NK/ T-cell lymphoma:clinical outcome, prognostic factors, and the effect of treatment mortality. Int J Radiat Oncol Biol Phys 54:182-190, 2002
 
29) Aviles A, Diaz NR, Neri N et al:Angiocentric nasal T/natural killer cell lymphoma:a single center study of prognostic factors in 108 patients. Clin Lab Haematol 22:215-220, 2000
PubMed
30) Ribrag V, Ell Hajj M, Janot F et al:Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 15:1123-1126, 2001
PubMed
31) Li Yx, Coucke PA, Li JY et al:Primary non-Hodgkin's lymphoma of the nasal cavity:prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 83:449-456, 1998
PubMed
32) Yamaguchi M, Kita K, Miwa H et al:Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76:2351-2356, 1995
PubMed
33) Drenou B, Lamy T, Amiot L et al:CD3-CD56+non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 89:2966-2974, 1997
PubMed
34) Imashuku S, Kuriyama K, Teramura T et al:Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 19:2665-2673, 2001
 
35) Kim BS, Kim TY, Heo DS et al:The efficacy of etoposide-containing regimen as the salvage therapy in extranodal NK/T cell lymphoma. Proc Am Soc Clin Oncol 22:591, 2003
 
36) Wong KE Chan JKC, Cheung MM et al:Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Am J Clin Pathol 115:266-270, 2001
 
37) Yamaguchi M, Ogawa S, Nomoto Y et al:Treatment outcome of nasal NK-cell lymphoma:a report of 12 consectively-diagnosed cases and review of the literature. J Clin Exp Hematopathol 41:93-99, 2001
 
38) Hirano M, Okamoto M, Maruyama F et al:Alternating noncross-resistant chemotherapy for non-Hodgkin's lymphoma of intermediate-grade and high-grade malignancy Cancer 69:772-777, 1993
 
39) Niitsu N, Okamoto M, Kuraishi Y et al:CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma:a pilot study. Eur J Hematol 65;188-194, 2000
 
40) 岡本昌隆, 丸山文夫, 長谷川明生ほか:Extranodal NK/T-celllymphoma, nasal type に対する浸潤領域照射と化学療法 (主に第3世代) の同時併用治療の安全性と有効性. 日リンパ網内系会誌 43:74, 2003
 
41) Shikama N, Ikeda H, Nakamura S et al:Localized aggressive non-Hodgkin's lymphoma of the nasal cavity:a surveyby the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys 51:1228-1233, 2001
PubMed
42) Aviles A, Neri N, Fernandez R et al:Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy Med Oncol 20:13-17, 2003
PubMed
43) Yong W, Zheng W, Zhang Y et al:L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 78:163-167, 2003
 
44) Egashira M, Kawamata N, Sugimoto K et al:P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 93:599-606, 1999
PubMed
45) Lei KI, Chan LY, Chan WY et al:Diagnostic and prognosticimplication of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res 8:29-34, 2002
PubMed
P.195 掲載の参考文献
1) Uchiyama T, Yodoi J, Sagawa K et al:Adult T-cell leukemia:clinical and hematologic features of 16 cases. Blood 50:481-492, 1977
PubMed
2) Tajima K:The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan:estimates of risk of ATL and its geographical and clinical features. The T-and B-cell Malignancy Study Group. Int J Cancer 45:237-243, 1990
 
3) Yamaguchi K:Human T-lymphotropic virus type 1 in Japan. Lancet 343:213-216, 1994
PubMed
4) Brick WG, Nalamolu Y, Jillella AP et al:Adult T-cell leukemia/lymphoma:a rare case in the USA and review of the literature. Leuk Lymphoma 43:127-132, 2002
PubMed
5) The Non-Hodgkin's lymphoma classification project:A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
 
6) Hinuma Y, Nagata K, Hanaoka M et al:Adult T-cell leukemia:antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Naatl Acad Sci USA 78:6476-6480, 1981
 
7) Shibata A, Aoyagi A, Aoki S:Adult T-cell leukemia observed at Niigata university hospital. Jpn J CLin Oncol 13:657-666, 1983
 
8) Shimoyama M:Diagnositic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. Br J Haematol 79:428-437, 1991
 
9) Tsukasaki K, Tsushima H, Yamamura M et al:Integration patterns of HTLV-I provirus in relation to the clinical course of ATL:frequent clonal change at crisis from indolent disease. Blood 89:948-956, 1997
 
10) Hanon E, Stinchcombe JC, Saito M et al:Fratricide among CD8+ T lymphocytes naturally infected with human T Cell lymphotropic virus type I. Immunity 13:657-664, 2000
PubMed
11) Popovic M, Sarin PS, Robert-Gurroff M et al:Isolation and transmission of human retrovirus (human t-cell leukemia virus). Science 219:856-859, 1983
PubMed
12) Yasunaga J, Matsuoka M:Leukemogenesis of adult T-cell leukemia. Int J Hematol 78:312-320, 2003
PubMed
13) Ishikawa T:Current status of therapeutic approaches to adult T-cell leukemia. Int J Hematol 78:304-311, 2003
PubMed
14) Hermine O, Bouscary D, Gessain A et al:Brief report:treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 332:1749-1751, 1995
PubMed
15) Bazarbachi A, Hermine O:Treatment of adult T-cell leukaemia/lymphoma:current strategy and future perspectives. Virus Res 78:79-92, 2001
PubMed
16) White JD, Wharfe G, Stewart DM et al:The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 40:287-294, 2001
PubMed
17) Yamada Y, Tomonaga M, Fukuda H et al:A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma:Japan Clinical Oncology Group Study 9303. Br J Haematol 113:375-382, 2001
 
18) 0hno R, Masaoka T, Shirakawa S et al:Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis (2,6-dioxopiperazine). The MST-16 Study Group. Cancer 71:2217-2221, 1993
 
19) Tsuda H, Takatsuki K, Ohno R et al:Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy. Br J Cancer 70:771-774, 1994
 
20) Yamada Y, Tomonaga M:The current status of therapy for adult T-cell leukaemia-lymphoma in Japan. Leuk Lymphoma 44:611-618, 2003
PubMed
21) Emmanouilides CE, Territo M:HTLV-I-associated myelopathy following allogeneic bone marrow transplantation. Bone Marrow Transplant 24:205-206, 1999
PubMed
22) Ljungman P, Lawler M, Asjo B et al:Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. Br J Haematol 88:403-405, 1994
 
23) Utsunomiya A, Miyazaki Y, Takatsuka Y et al:Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 27:15-20, 2001
PubMed
24) Kami M, Hamaki T, Miyakoshi S et al:Allogeneic haematopoietic stem cell transplantation for the treatment of adult T cell leukaemia/lymphoma. Br J Haematol 120:304-309, 2003
PubMed
25) 0gata M, Ogata Y, Imamura T et al:Successful bone marrow transplantation from an unrelated donor in a patient with adult T cell leukemia. Bone Marrow Transplant 30:699-701, 2002
 
P.206 掲載の参考文献
1) Stein H, Delsol G, Pileri S et al:Chapter 8:Hodgkin lymphoma. In:World Health Organization Classification of Tumours, Pathology & Genetics, Tumours of Haematopoietic and Lymphoid Tissues, ed. by Jaffe ES, Harris NL, Stein H et al, IARC Press, Lyon, 2001, pp. 237-253
 
2) Lymphoma Study Group of Japanese Pathologists:The world health organization classification of malignant lymphomas in japan:Incidence of recently recognized entities. Pathol Int 206 50:696-702, 2000
 
3) Hodgkin T:On some morbid appearances of the absorbent glands and spleen. Med Chir Soc Tr 17:68-114, 1832
 
4) Wilks S:Cases of enlargement of the lymphatic glands and spleen (or Hodgkin's disease) with remarks. Guys Hosp Rep 11:56-67, 1865
 
5) Stein H, Mason DY, Gerdes J et al:The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neo-plastic lymphoid tissue:evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848-858, 1985
 
6) Tamaru J, Mikata A, Azuma K et al:Reciprocal/dichotomic expression of vimentin and B cell differentiation antigens in Reed-Sternberg's cells. Virchows Arch A Pathol Anat Histopathol 416:213-220, 1990
 
7) Tamaru J, Hummel M, Zemlin M et al:Hodgkin's disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. Blood 84:708-715, 1994
 
8) Kuppers R, Rajewsky K, Zhao M et al:Hodgkin disease:Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 91:10962-10966, 1994
 
9) Harris NL, Jaffe ES, Stein H et al:A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
 
10) Bennett MH, MacLennan KA, Easterling MJ et al:The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease:an analysis of 271 non-laparotomised cases (BNLI report no. 22). Clin Radiol 34:497-501, 1983
PubMed
11) Anagnostopoulos I, Hansmann ML, Franssila K et al:European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease:histologic and immunohistologic analysis of submitted ceses reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96:1889-1899, 2000
 
12) Seitz V, Hummel M, Marafioti T et al:Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 95:3020-3024, 2000
PubMed
13) Foss HD, Reusch R, Demel G et al:Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 94:3108-3113, 1999
 
14) Van den Berg A, Visser L, Poppema S:High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein in Hodgkin's lymphoma. Am J Pathol 154:1685-1691, 1999
 
15) Stein H, Marafioti T, Foss HD et al:Down-regulation of BOB. 1/OBE 1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 97:496-501, 2001
 
16) Marafioti T, Hummel M, Anagnostopoulos I et al:Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 337:453-458, 1997
PubMed
17) Kuppers R, Klein U, Hansmann ML et al:Cellular origin of human B-cell lymphomas. N Engl J Med 341:1520-1529, 1999
 
18) 安見和彦, 田丸淳一, 浅井隆善ほか:Proliferating cell nuclear antigen (PCNA) による悪性リンパ腫の検索. 日本網内系学会会誌 32:301-314, 1992
 
19) Wood KM, Roff M, Hay RT:Defective IκB αin Hodgkin cell lines with constitutively active NF-κB. Oncogene 16:2131-2139, 1998
 
20) Krappmann D, Emmerich E Kordes U et al:Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 18:943-953, 1999
 
21) Schwering I, Brauninger A, Klein U et al:Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101:1505-1512, 2003
 
22) Marafioti T, Pozzobon M, Hansmann ML et al:Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood 103:188-193, 2004
PubMed
23) Gravel S, Delsol G, Al Saati T:Single-cell analysis of the t(14;18) (q32;q21) chromosomal translocation in Hodgkin's disease demonstrates the absence of this translocation in neo-plastic Hodgkin and Reed-Sternberg cells. Blood 91:2866-2874, 1998
 
24) Lamant L, Meggetto F, al Saati T et al:High incidence of the t(2;5) (p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 87:284-291, 1996
 
25) Wellmann A, Thieblemont C, Pittaluga S et al:Detection of differentially expressed genes in lymphomas using cDNA arrays:identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 96:398-404, 2000
PubMed
P.219 掲載の参考文献
1) Marafioti T, Hummel M, Anagnostopoulos I et al:0rigin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 337:453-458, 1997
PubMed
2) Ohno T, Stribley JA, Wu G et al:Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 337:459-465, 1997
PubMed
3) Kuppers R, Klein U, Schwering I et al:Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest 111:529-537, 2003
PubMed
4) Lukes RJ, Butler JJ:The pathology and nomenclature of Hodgkin's disease. Cancer Res 26:1063-1083, 1966
PubMed
5) Harris NL, Jaffe ES, Stein H et al:A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
 
6) Jaffe ES, Harris NL, Stein H et al (ed):In:World Health Organization Classification of Tumors. Pathology & Genetics. Tumor of Hematopoietic and Lymophoid Tissues. IARC Press, Lyon, 2001
 
7) Kanzler H, Kuppers R, Hansmann ML et al:Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the out-growth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184:1495-1505, 1996
 
8) Gandhi MK, Tellam JT, Khanna R:Epstein-Barr virus-associated Hodgkin's lymphoma. Br J Haematol 125:267-281, 2004
PubMed
9) Lister TA, Crowther D, Sutcliffe SB et al:Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease:Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
PubMed
10) Ng AK, Mauch PM:Radiation therapy in Hodgkin's lymphoma. Semin Hematol 36:290-302, 1999
PubMed
11) Specht L, Gray RG, Clarke MJ et al:Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease:ameta-analysis of 23 randomized trials involving 3, 888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 16:830-843, 1998
 
12) Salloum E, Doria R, Schubert W et al:Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 14:2435-2443, 1996
PubMed
13) Press OW LeBlanc M, Lichter AS et al:Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage I A to II A Hodgkin's disease. J Clin Oncol 19:4238-4244, 2001
 
14) Devita VT Jr, Serpick AA, Carbone PP:Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:881-895, 1970
PubMed
15) Bonadonna G, Zucali R, Monfardini S et al:Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP Cancer 36:252-259, 1975
PubMed
16) Bonadonna G, Valagussa P, Santoro A:Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 104:739-746, 1986
 
17) Canellos GP, Anderson JR, Propert KJ et al:Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
PubMed
18) Takenaka T, Mikuni C, Miura A et al:Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone ) and ABVd ( adriamycin, bleomycin, vinblastine, dacarbazine ) in clinical stage II-IV Hodgkin's disease:a multicenter phase II study (JCOG 8905). Jpn J Clin Oncol 30:146-152, 2000
PubMed
19) 2000年前期定期モニタリングレポートJCOG9305 (phaseII):JCOG共同研究報告書 (第13集). JCOG データセンター編, 2000, pp. 418-435
 
20) Goldie JH, Coldman AJ:A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat , Rep 63:1723-1733, 1979
 
21) Coldman AJ, Goldie JH:Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 14:29-33, 1987
PubMed
22) Klimo P, Connors JM:MOPP/ABV hybrid program:combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 3:1174-1182, 1985
PubMed
23) Klimo P, Connors JM:An update on the Vancouver experiencein the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program. Semin Hematol 25 (suppl 2):S34-S40, 1988
 
24) Viviani S, Bonadonna G, Santoro A et al:Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease:ten-year results. J Clin Oncol 14:1421-1430, 1996
PubMed
25) Duggan D, Petroni G, Johnson J et al:MOPP/ABV versus ABVD for advanced Hodgkin's disease. A preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). Proc Am Soc Clin Oncol 16:12a, 1997 (abstr)
 
26) Sieber M, Rueffer U, Tesch H et al:Rapidly alternating COPP+ABV+IMEP (CAI) is equally effective as alternating COPP+ABVD (CA) for Hodgkin's disease:Final results of two randomized trials for intermediate (HD5 protocol) and advanced (HD6 protocol) stages. Fourth International symposium on Hodgkin's disease, Koln, Germany, 1998. Leuk Lymphoma 29 (suppl 1):23a, 1998 (abstr)
 
27) Hasenclever D, Diehl V:A prognostic score for advanced Hodgkin's disease. N Engl J Med 339:1506-1514, 1998
 
28) Carde P, MacKintosh FR, Rosenberg S:A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1:146-153, 1983
PubMed
29) Horning SJ, Rosenberg SA, Hoppe RT:Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease:an update. Ann Oncol 7(suppl 4):S105-S108, 1996
 
30) Bartlett NL, Rosenberg SA, Hoppe RT et al:Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced stage Hodgkin's disease:a preliminary report. J Clin Oncol 13:1080-1088, 1995
PubMed
31) Horning SJ, Hoppe RT, Breslin S et al:Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease:mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002
 
32) Horning SJ, Williams J, Bartlett NL et al:Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease:Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 18:972-980, 2000
 
33) Diehl V, Sieber M, Ruffer U et al:BEACOPP:an intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 8:143-148, 1997
PubMed
34) Tesch H, Diehl V, Lathan B et al:Moderate dose escalation foradvanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine procarbazine, and prednisone scheme and adjuvant radiotherapy:astudy ofthe German Hodgkin's Lymphoma Study Group. Blood 92:4560-4567, 1998
 
35) Diehl V, Franklin J, Pfreundschuh M et al:German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
 
36) Diehl V, Franklin J, Hasenclever D et al:BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma:Interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 16:3810-3821, 1998
 
37) Sieber M, Engert A, Diehl V:Treatment of Hodgkin's disease:results and current concepts of the German Hodgkin's Lymphoma Study Group. Ann Oncol 11(suppl 1):S81-S85, 2000
 
38) Reuss K, Engert A, Tesch H et al:Current clinical trials in Hodgkin's disease. Ann Oncol 7(suppl 4):S109-S113, 1996
 
39) Diehl VD, Stein H, Hummel M et al:III Treatment of refractory or relapsed Hodgkin's lymphoma. Hodgkin's lymphoma:Biology and treatment strategies for primary, refractory, and relapsed disease. Hematology 203, American Society of Hematology Education Program Book, pp. 225-247, 2003
 
40) Loeffler M, Brosteanu O, Hasenclever D et al:Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 16:818-829, 1998
 
41) Aleman BM, Raemaekers JM, Tirelli U et al:Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348:2396-2406, 2003
PubMed
42) Carella AM, Carlier P, Congiu A et al:Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant 8:99-103, 1991
PubMed
43) Fleury J, Legros M, Colombat P et al:High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease. Leuk Lymphoma 20:259-266, 1996
PubMed
44) Federico M, Clo V, Carella AM:High-dose therapy autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy:analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol. EBMT/ANZLG/Intergroup HD01 Trial. Leukemia 10(suppl 2):S69-S71, 1996
 
45) Laport GE Williams SF:The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 25:503-517, 1998
 
46) Sweetenham JW Carella A, Taghipour G et al:High dose therapy (HDT) and autologous stem cell transplantation (ASCT) for adult parients with primary refractory Hodgkin's disease (HD).-Thirty recent of patients are progression free at 5 years:data from 290 patients reported to the RBMT Bone Marrow Transplant 19(suppl 1):S152, 1997
 
47) Chopra R, McMillan AK, Linch DC et al:The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 81:1137-1145, 1993
PubMed
48) Horning SJ, Chao NJ, Negrin RS et al:High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease:analysis of the Stanford University results and prognostic indices. Blood 89:801-813, 1997
PubMed
49) Lazarus HM, Rowlings PA, Zhang MJ et al:Autotransplants for Hodgkin's disease in patients never achieving remission:a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17:534-545, 1999
PubMed
50) Andre M, Henry-Amar M, Pico JL et al:Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure:a case-control study Societe Francaise de Greffe de Moelle. J Clin Oncol 17:222-229, 1999
PubMed
51) Linch DC, Winfield D, Goldstone AH et al:Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease:results of a BNLI randomised trial. Lancet 341:1051-1054, 1993
PubMed
52) Schmitz Z, Sextro M, Pfistner B et al:High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease:Final results of a randomized GHSG and EBMT trial (HD-R1). Proc Amer Soc Clin Oncol 1:2a, 1999
 
53) Milpied N, Fielding AK, Pearce RM et al:Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 14:1291-1296, 1996
PubMed
54) Carella AM, Prencipe E, Pungolino E et al:Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy. Leuk Lymphoma 21:63-70, 1996
PubMed

書評

最近チェックした商品履歴

Loading...